Prazosin HCl

PreclinicalSmall molecule

Pfizer

Prazosin HCl is one of 4 small molecule programs targeting Autonomic Dysreflexia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autonomic DysreflexiaActive, not recruiting

Autonomic DysreflexiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Autonomic Dysreflexia

#DrugCompanyPhaseTrials

Inversine

TTargacept Inc.

Approved

1 2

Botox

AbbVie

Approved

1 3

Toviaz

Pfizer

Phase 2

1 4

Prazosin HCl

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Autonomic Dysreflexia1 trial

Prazosin Vibrostimulation Autonomic Dysreflexia and Spinal Cord Injury Study

Completed·UUniversity of British Columbia·N/A·NCT00175682·7 enrolled

Adult1 trial

A Study to Learn How Different Forms of the Study Medicine Called Prazosin Are Taken up Into the Blood in Healthy Adults

Recruiting· Pfizer logo

Pfizer·Phase 1·NCT07231978·72 enrolled

Unspecified1 trial

Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules

Completed· Pfizer logo

Pfizer·Phase 1·NCT04967443·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Prazosin HCl. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Prazosin HCl compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Prazosin HCl. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Pfizer

Prazosin HCl

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Autonomic Dysreflexia1 trial

Adult1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News